Gain Therapeutics, Inc. (GANX)

NASDAQ: GANX · IEX Real-Time Price · USD
3.10
+0.03 (0.98%)
Nov 25, 2022 4:00 PM EDT - Market closed
0.98%
Market Cap 36.72M
Revenue (ttm) 210,660
Net Income (ttm) -16.14M
Shares Out 11.88M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,730
Open 3.08
Previous Close 3.07
Day's Range 3.06 - 3.1
52-Week Range 2.33 - 7.93
Beta n/a
Analysts Buy
Price Target 19.64 (+533.5%)
Earnings Date Nov 11, 2022

About GANX

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B,... [Read more]

Industry Biotechnology
IPO Date Mar 18, 2021
Employees 25
Stock Exchange NASDAQ
Ticker Symbol GANX
Full Company Profile

Financial Performance

In 2021, GANX's revenue was $164,994, an increase of 471.29% compared to the previous year's $28,881. Losses were -$13.89 million, 288.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for GANX stock is "Buy." The 12-month stock price forecast is 19.64, which is an increase of 533.55% from the latest price.

Price Target
$19.64
(533.55% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson's Disease Therapeutic, GT-02287

2 weeks ago - GlobeNewsWire

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

Outgoing CEO Eric Richman will continue to serve as a member of the board of directors and serve as a senior advisor to the Company Outgoing CEO Eric Richman will continue to serve as a member of the bo...

2 months ago - GlobeNewsWire

Gain Therapeutics to Present Data at Upcoming Medical Meetings

Presenting Preclinical Data at 2022 International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain

2 months ago - GlobeNewsWire

Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference

BETHESDA, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computationa...

2 months ago - GlobeNewsWire

Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -22.86% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update

Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Utility in Parkinson's Disease and Gaucher D...

3 months ago - GlobeNewsWire

Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy?

Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Gain Therapeutics to Participate at the Jefferies Healthcare Conference

BETHESDA, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational...

5 months ago - GlobeNewsWire

Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference

BETHESDA, Md., May 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational ...

6 months ago - GlobeNewsWire

Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson's Disease and Gaucher's Disease.

6 months ago - GlobeNewsWire

Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium

Lead compound GT-02329 increases GCase levels and activity, depletes toxic substrates glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) in relevant Gaucher disease (GD) models Lead compound GT-...

6 months ago - GlobeNewsWire

Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease ...

Lead Compound GT-02287 is Brain Penetrant, Reduces Alpha-synuclein, and Increases Dopamine in Relevant Neuronal Models Lead Compound GT-02287 is Brain Penetrant, Reduces Alpha-synuclein, and Increases D...

6 months ago - GlobeNewsWire

Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

BETHESDA, Md., April 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming the drug discovery paradigm with structurally ta...

6 months ago - GlobeNewsWire

Gain Therapeutics Shares Skyrocket After Preclinical Data From Parkinson's Program

Gain Therapeutics Inc (NASDAQ: GANX) has presented new preclinical data from its Parkinson's Disease (PD) program at the 2022 Synuclein Meeting.  The data show that the lead compound GT-02287 increases ...

7 months ago - Benzinga

Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at the 2022 ...

Lead candidate GT-02287 is bioavailable, increases GCase levels, depletes alpha-synuclein, increases lysosomal health, and improves neuronal network and survival in relevant neuronal cell models Lead ca...

7 months ago - GlobeNewsWire

Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sph...

Study results demonstrate lead compounds increase GCase protein levels, activity and co-localization in the lysosome, and decrease toxic substrate accumulation Study results demonstrate lead compounds i...

7 months ago - GlobeNewsWire

Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update

$36.88 Million in cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash position to transition the Company's lead program into clinical trials --- Compelling preclinic...

8 months ago - GlobeNewsWire

Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs

Gain Therapeutics Inc (NASDAQ: GANX) has presented new preclinical data from its Parkinson's and Alzheimer's Disease programs.  These results were highlighted at the International Conference on Alzheime...

8 months ago - Benzinga

Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences

- Oppenheimer 32 nd Annual Healthcare Conference -

8 months ago - GlobeNewsWire

Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day

BETHESDA, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming and accelerating drug discovery with structurally...

9 months ago - GlobeNewsWire

Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day

Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to D...

9 months ago - GlobeNewsWire

Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference

BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never b...

10 months ago - GlobeNewsWire